Inovio Pharmaceuticals, Inc. – NASDAQ:INO
Inovio Pharmaceuticals stock price today
$1.92
+0.04
+2.67%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 5 hours
Inovio Pharmaceuticals stock price monthly change
-83.47%
month
Inovio Pharmaceuticals stock price quarterly change
-83.47%
quarter
Inovio Pharmaceuticals stock price yearly change
+264.59%
year
Inovio Pharmaceuticals key metrics
Market Cap | 63.89M |
Enterprise value | N/A |
P/E | -0.57 |
EV/Sales | -1.37 |
EV/EBITDA | 0.05 |
Price/Sales | 0.01 |
Price/Book | N/A |
PEG ratio | -0.02 |
EPS | -5.54 |
Revenue | N/A |
EBITDA | -128.49M |
Income | -124.93M |
Revenue Q/Q | -100% |
Revenue Y/Y | -92.95% |
Profit margin | -2726.67% |
Oper. margin | -2607.35% |
Gross margin | 0% |
EBIT margin | -2607.35% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeInovio Pharmaceuticals stock price history
Inovio Pharmaceuticals stock forecast
Inovio Pharmaceuticals financial statements
| Jun 2023 | 225.97K | -35.53M | -15725.26% |
|---|---|---|---|
| Sep 2023 | 388.44K | -33.92M | -8734.77% |
| Dec 2023 | 102.65K | -25.00M | -24357.91% |
| Mar 2024 | 0 | -30.46M |
| Dec 2023 | 102.65K | -25.00M | -24357.91% |
|---|---|---|---|
| Mar 2024 | 0 | -30.46M | |
| Oct 2025 | 100K | -23.05M | -23058.6% |
| Dec 2025 | 75.1M | 27.94M | 37.22% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 233037960 | 63.66M | 27.32% |
|---|---|---|---|
| Sep 2023 | 193097198 | 54.93M | 28.45% |
| Dec 2023 | 172944423 | 55.59M | 32.15% |
| Mar 2024 | 129114165 | 34.67M | 26.85% |
| Jun 2023 | -32.31M | 53.90M | 2.88M |
|---|---|---|---|
| Sep 2023 | -36.84M | -5.49M | 698.63K |
| Dec 2023 | -26.27M | 19.94M | 1.83M |
| Mar 2024 | -28.75M | 45.38M | -11.36M |
Inovio Pharmaceuticals alternative data
| Aug 2023 | 184 |
|---|---|
| Sep 2023 | 135 |
| Oct 2023 | 135 |
| Nov 2023 | 135 |
| Dec 2023 | 184 |
| Jan 2024 | 184 |
| Feb 2024 | 184 |
| Mar 2024 | 122 |
| Apr 2024 | 122 |
| May 2024 | 122 |
| Jun 2024 | 122 |
| Jul 2024 | 122 |
Inovio Pharmaceuticals other data
51.15%
+7.76%
of INO is owned by hedge funds
154
-21
111.97M
+21.37M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jul 2022 | 0 | 2000 |
| Aug 2022 | 0 | 11875 |
| Feb 2023 | 0 | 11668 |
| Mar 2023 | 0 | 5833 |
| Jun 2023 | 0 | 5700 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | SUMNER MICHAEL JOHN officer: Chief Medical Officer | Common Stock | 2,917 | N/A | N/A | ||
Option | SUMNER MICHAEL JOHN officer: Chief Medical Officer | Restricted Stock Unit | 2,917 | N/A | N/A | ||
Option | MILLER ANN CALBY director | Common Stock | 2,166 | N/A | N/A | ||
Option | MILLER ANN CALBY director | Restricted Stock Unit | 2,166 | N/A | N/A | ||
Option | BENITO SIMON X director | Common Stock | 2,166 | N/A | N/A | ||
Option | BENITO SIMON X director | Restricted Stock Unit | 2,166 | N/A | N/A | ||
Option | SHEPARD JAY director | Common Stock | 2,166 | N/A | N/A | ||
Option | SHEPARD JAY director | Restricted Stock Unit | 2,166 | N/A | N/A | ||
Option | KIES PETER officer: CFO | Common Stock | 4,771 | N/A | N/A | ||
Option | KIES PETER officer: CFO | Restricted Stock Unit | 4,771 | N/A | N/A |
| Patent |
|---|
Application Filling date: 25 Apr 2022 Issue date: 25 Aug 2022 |
Application Filling date: 25 Apr 2022 Issue date: 25 Aug 2022 |
Application Filling date: 18 Mar 2022 Issue date: 7 Jul 2022 |
Application Filling date: 7 Mar 2022 Issue date: 16 Jun 2022 |
Grant Filling date: 13 Dec 2018 Issue date: 24 May 2022 |
Grant Filling date: 13 Dec 2018 Issue date: 24 May 2022 |
Grant Filling date: 9 Jul 2019 Issue date: 17 May 2022 |
Application Filling date: 23 Dec 2021 Issue date: 14 Apr 2022 |
Application Filling date: 22 Dec 2021 Issue date: 14 Apr 2022 |
Application Filling date: 17 Dec 2021 Issue date: 14 Apr 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 13 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 6 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. J. Joseph Kim (1969) Chief Executive Officer, Pres & Director | $1,210,000 |
| Mr. Peter D. Kies (1963) Chief Financial Officer | $653,910 |
| Dr. Laurent M. Humeau (1967) Chief Scientific Officer | $637,370 |
| Dr. Jacqueline E. Shea Ph.D. (1966) Chief Operating Officer | $637,320 |
Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway
Precigen: RRP Targeting With AdenoVerse Technology Platform
Inovio: Long-Term Biotech To Own With Several Catalysts Expected In 2022
SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying
Inovio Undervalued On Potential 2022 Catalyst
Inovio Pharmaceuticals: Forget The COVID Pump, And Keep Your Eye On The Oncology Side
Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal
ViacomCBS: Now Is The Time To Buy
Inovio Has 4 Sources Of Potential Value
-
What's the price of Inovio Pharmaceuticals stock today?
One share of Inovio Pharmaceuticals stock can currently be purchased for approximately $1.92.
-
When is Inovio Pharmaceuticals's next earnings date?
Unfortunately, Inovio Pharmaceuticals's (INO) next earnings date is currently unknown.
-
Does Inovio Pharmaceuticals pay dividends?
No, Inovio Pharmaceuticals does not pay dividends.
-
How much money does Inovio Pharmaceuticals make?
Inovio Pharmaceuticals has a market capitalization of 63.89M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 91.89% to 832.01K US dollars.
-
What is Inovio Pharmaceuticals's stock symbol?
Inovio Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "INO".
-
What is Inovio Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Inovio Pharmaceuticals?
Shares of Inovio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Inovio Pharmaceuticals's key executives?
Inovio Pharmaceuticals's management team includes the following people:
- Dr. J. Joseph Kim Chief Executive Officer, Pres & Director(age: 56, pay: $1,210,000)
- Mr. Peter D. Kies Chief Financial Officer(age: 62, pay: $653,910)
- Dr. Laurent M. Humeau Chief Scientific Officer(age: 58, pay: $637,370)
- Dr. Jacqueline E. Shea Ph.D. Chief Operating Officer(age: 59, pay: $637,320)
-
How many employees does Inovio Pharmaceuticals have?
As Jul 2024, Inovio Pharmaceuticals employs 122 workers.
-
When Inovio Pharmaceuticals went public?
Inovio Pharmaceuticals, Inc. is publicly traded company for more then 26 years since IPO on 8 Dec 1998.
-
What is Inovio Pharmaceuticals's official website?
The official website for Inovio Pharmaceuticals is inovio.com.
-
Where are Inovio Pharmaceuticals's headquarters?
Inovio Pharmaceuticals is headquartered at 660 West Germantown Pike, Plymouth Meeting, PA.
-
How can i contact Inovio Pharmaceuticals?
Inovio Pharmaceuticals's mailing address is 660 West Germantown Pike, Plymouth Meeting, PA and company can be reached via phone at +267 440 4200.
Inovio Pharmaceuticals company profile:
Inovio Pharmaceuticals, Inc.
inovio.comExchange:
NASDAQ
Full time employees:
127
Industry:
Biotechnology
Sector:
Healthcare
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
660 West Germantown Pike
Plymouth Meeting, PA 19462
Plymouth Meeting, PA 19462
CIK: 0001055726
ISIN: US45773H4092
CUSIP: 45773H201
